Experimental study of mitomycin C, the drug is cell cycle non-specific drugs, in 1955 by Japanese scholar Qin rattan trees isolated in Tokyo, two kinds of soil actinomycetes Strepto-myees caespitosus, found that the medium can inhibit tumor effect. 1958, if the wood has improved extraction method and found a with A, B different purple crystals, have a stronger anti-tumor effects, known as Mitomycin Co 1965 Shanghai Institute of Materia Medica Chinese Academy of Sciences Yingtan from our soil in Jiangxi Province strains isolated from H2760 strain derived from self-radiation adriamycin, and prove Mitomycin C with foreign reported the same. See its structure, stuffed with benzene, urethane, and the role of ethylene-imino groups of three. Its role to some extent similar with the melted agents, depolymerization of the cell DNA, while blocking DNA replication, thereby inhibiting cell division.
MMC in the body by NADPH cytochrome P450 reductase or DT-diaphorase role, reduced to burnt bifunctional agent, which from time to time with the DNA strand cross-link chain, thereby inhibiting DNA synthesis. Experimental Study of mitomycin C, the other, MMC led to an increase of oxygen free radicals and anti-tumor activity may also be relevant. Hypoxic cells more sensitive to MMC. Low concentration of cells decreased when the GI, S and Gz phase of the cell increased, indicating that GI phase cells most sensitive to it. MMC broad spectrum anti-tumor, a variety of eating rodents transplanted mice with human tumors and inhibit tumor graft. Doses were ineffective when used alone the 6-TG and MMC such as joint application, on early mouse leukemia L12l0 significant effect; and BLM effective combination on rat AH66 tumor; and Me-CCNU, or ADM, or Ara-C combination therapy was inoculated The Yoshida sarcoma rat stomach, is more effective than single drug; with CTX and MTX combination therapy of leukemia P388 and L12l0 a synergistic effect; combination with ADM on the B16 melanoma and colon cancer, 26 have synergistic effect. DDP increase the MMC on the EMT6 tumor cytotoxicity.
Experimental study of mitomycin C in mice and rats, the LDso was 4.3–6.7mg/kg intravenous and 2.5 – 3.1mg / Zhi, intraperitoneal administration, respectively 8.4mg/kg and 4.7 LDso – 5.Omg / Zhi. The product IV disappeared quickly from plasma, the plasma half-life of intravenous 30mg 17min, intravenous injection 30mg, 20mg and 10mg drug peak plasma concentration was 2.4g/ml, 1.7g/ml and O.5 in g / ml. In all tissues can be detected in the product to the muscles, heart, lung and ascites in higher concentrations in brain, liver, spleen and skin tissue drug concentration is very low, not through the blood – brain barrier. It is mainly through hepatic metabolism, the urine drug dose given 3% – 18%.